Search results for "ADHERENCE"

showing 10 items of 277 documents

Real-world Adherence and Persistence with Bisphosphonate Therapy in Postmenopausal Women: A Systematic Review

2018

Abstract Purpose Bisphosphonate therapy is a well-established and effective treatment for postmenopausal osteoporosis and the prevention of osteoporotic fracture. However, poor adherence to and poor persistence with bisphosphonate therapy may reduce its benefits. Previous studies have documented the poor rates of adherence and persistence among postmenopausal women with osteoporosis. The objective of this systematic literature review was to evaluate adherence, persistence, and the impact of adherence and persistence on fracture risk in postmenopausal women with diagnosed osteoporosis. Methods Articles eligible for review included observational studies of the real-world use of bisphosphonate…

medicine.medical_specialtymedicine.medical_treatmentOsteoporosisMEDLINE02 engineering and technology030204 cardiovascular system & hematologyMedication AdherencePersistence (computer science)03 medical and health sciences020210 optoelectronics & photonics0302 clinical medicineInternal medicine0202 electrical engineering electronic engineering information engineeringmedicineHumansPharmacology (medical)Osteoporosis PostmenopausalPharmacologyBone Density Conservation AgentsDiphosphonatesbusiness.industryBisphosphonatemedicine.diseasePostmenopauseMenopauseObservational Studies as TopicTreatment OutcomeSystematic reviewFemaleObservational studybusinessOsteoporotic FracturesBiomedical sciencesClinical Therapeutics
researchProduct

Pharmacokinetics of new oral anticoagulants: implications for use in routine care

2018

Introduction: Since 2008, new oral anticoagulants (NOACs) have been approved for the prevention of venous thromboembolism (VTE) in patients receiving hip or knee replacement surgery, prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF), treatment of deep vein thrombosis (DVT), and pulmonary embolism (PE). Premarketing randomized clinical trials (RCTs) of NOACs demonstrated their non-inferiority in terms of efficacy vs. warfarin (traditional oral anticoagulant–TOA), with lower risk of serious adverse drug reactions, especially cerebral hemorrhages. In clinical practice, pharmacokinetic aspects of NOACs have to be carefully taken into account to …

medicine.medical_treatmentnew oral anticoagulantsAdministration OralKnee replacement030204 cardiovascular system & hematologyToxicologyAdherence Bleeding Interactions New oral anticoagulants Over- and under-dosage Persistence Pharmacokinetics Real World Evidence0302 clinical medicineAtrial Fibrillationover- and underdosage030212 general & internal medicinepharmacokineticStrokeRoutine careRandomized Controlled Trials as Topicnew oral anticoagulantAtrial fibrillationpersistenceVenous ThromboembolismGeneral MedicinePulmonary embolismStrokepharmacokineticsHumanmusculoskeletal diseasesmedicine.medical_specialtyinteractionHemorrhageMedication Adherence03 medical and health sciencesPharmacokineticsmedicineHumansReal World EvidenceIn patientOver- and under-dosagecardiovascular diseasesreal-world evidenceIntensive care medicineAgedPharmacologybusiness.industryAnticoagulantAnticoagulantsinteractionsbleedingmedicine.diseaseAdherencePulmonary EmbolismbusinessVenous thromboembolismExpert Opinion on Drug Metabolism & Toxicology
researchProduct

Nonadherence in outpatient thrombosis prophylaxis with low molecular weight heparins after major orthopaedic surgery

2010

Background: According to some current guidelines, extended thromboprophylaxis after hip and knee arthroplasties is recommended. Outpatient prophylaxis with low molecular weight heparins (LMWH) is an important part of this prophylaxis, although the rates of adherence to these regimens is not known. Questions/purposes: We determined (1) the degree of nonadherence (NA) of patients with LMWH outpatient prophylaxis, and (2) whether specific independent factors explain NA. Methods: NA was determined by syringe count and by indirect and direct questions to patients. We defined six different NA indicators. To identify factors explaining LMWH NA, we used three different logistic regression models. R…

musculoskeletal diseasesMaleQuestionnairesmedicine.medical_specialtyHealth Knowledge Attitudes PracticeTime Factorsmedicine.drug_classmedicine.medical_treatmentArthroplasty Replacement HipLow molecular weight heparinRisk AssessmentInjectionsMedication AdherenceAmbulatory careFibrinolytic AgentsClinical ResearchRisk FactorsInternal medicineSurveys and QuestionnairesGermanyAmbulatory CareMedicineHumansOrthopedics and Sports Medicine/dk/atira/pure/core/keywords/559092180Arthroplasty Replacement KneeAgedbusiness.industryAnticoagulantHealth sciencesThrombosisGeneral MedicineHeparinHeparin Low-Molecular-Weightmedicine.diseaseThrombosisArthroplastySurgeryTelephoneLogistic ModelsTreatment OutcomeOrthopedic surgerySurgeryFemalebusinessFibrinolytic agentmedicine.drug
researchProduct

COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adju…

2014

5 Office-based Professional Association Gynecologic Oncologists e.V. in Germany (BNGO e.V.), Berlin; 6 Background: This prospective study evaluated the relationship between arthralgia and compliance during the first year of adjuvant anastrozole therapy in postmenopausal women with hormone receptor-positive early breast cancer. Patients and methods: COMPliance and Arthralgia in Clinical Therapy (COMPACT) was an open-label, multicenter, noninterventional study conducted in Germany. Patients had started adjuvant anastrozole 3-6 months before the study start. The primary end points were arthralgia, compliance, and the relationship between compliance and arthralgia, assessed at specific time poi…

musculoskeletal diseasesmedicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.medical_treatmentSpecific timeAnastrozoleBreast NeoplasmsAnastrozoleMedication AdherenceBreast cancerInternal medicineNitrilesmedicineHumansProspective Studiesskin and connective tissue diseasesProspective cohort studyAgedbusiness.industryDrug SubstitutionIncidence (epidemiology)IncidenceHematologyMiddle AgedTriazolesmedicine.diseaseArthralgiaSurgeryCompliance (physiology)Clinical therapyTreatment OutcomeOncologyChemotherapy AdjuvantFemalebusinessAdjuvantmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Day and Night Control of COPD and Role of Pharmacotherapy: A Review

2020

Abstract The topic of 24-hour management of COPD is related to day-to-night symptoms management, specific follow-up and patients’ adherence to therapy. COPD symptoms strongly vary during day and night, being worse in the night and early morning. This variability is not always adequately considered in the trials. Night-time symptoms are predictive of higher mortality and more frequent exacerbations; therefore, they should be a target of therapy. During night-time, in COPD patients the supine position is responsible for a different thoracic physiology; moreover, during some sleep phases the vagal stimulation determines increased bronchial secretions, increased blood flow in the bronchial circ…

nightLABAReviewMuscarinic AntagonistsSettore MED/10 - Malattie Dell'Apparato Respiratoriocopd – symptoms – dyspnea – night – sleep – follow-up – adherence – circadian lama – laba – icsAdherence; Circadian; COPD; Dyspnea; Follow-up; Night; Sleep; SymptomsPulmonary Disease Chronic ObstructiveAdrenal Cortex HormonesAdministration InhalationSettore MED/10follow-upCOPDHumansadherencesleepAdrenergic beta-2 Receptor Agonistslcsh:RC705-779Circadianlcsh:Diseases of the respiratory systemdyspnearespiratory tract diseasesBronchodilator Agentscircadian LAMAICSsymptomsAdherence Circadian COPD Dyspnea Follow-up Night Sleep SymptomsInternational Journal of COPD
researchProduct

The Psychological Risks Associated With the Non-medical Switch From Biologics to Biosimilars

2021

Biological products are therapeutic agents produced using a living system or organism. In many cases, access to these products is limited due to their expensive cost (Chow et al., 2011). A biosimilar is a biological product that is highly similar (not identic) to, and has no clinically meaningful differences from, an existing reference biological product on the market (Desai et al., 2020). “Non-medical” switching is the switching of a patient's medicine for reasons other than the patient's health and safety, like the reduction of costs (Dolinar et al., 2019).

oncologyshared decision-makingnocebo effectrheumatologyadherence
researchProduct

Adherence to oral hormonal anticancer agents in breast cancer.

2022

There is an increasing trend towards using oral antitumoral agents in oncological patients. Compared to parenteral therapy, oral treatment offers convenience for both the patient and the healthcare system, with similar efficacy. However, the benefit deriving from oral drugs will be obtained only if patients adhere strictly to the treatment. Medical oncologists must therefore seek to optimize patient adherence. Breast cancer patients, particularly, are often treated with oral hormonal anticancer agents. In this review, we summarized evidence about adherence of breast cancer patients to oral hormonal anticancer agents and the consequences of poor compliance, the barriers to oral treatment an…

oral antitumoral agentsCancer Researchbreast cancerOncologyAdherenceadjuvant endocrine therapyGeneral MedicineTumori
researchProduct

Appropriateness of requests for human serum albumin at the University Hospital of Palermo, Italy: a prospective study

2015

Abstract OBJECTIVE: First, to assess the appropriateness of requests for albumin using current guidelines; second, to evaluate physicians' compliance with this protocol. DESIGN: Descriptive, prospective study. SETTING: 'Paolo Giaccone' University Hospital in Palermo (Italy). PARTICIPANTS: The six departments with the highest orders for albumin. INTERVENTION: An experimental, pharmacist-driven process for daily orders of albumin was activated over a period of 1 month. Pharmacy personnel handed out order forms on six different wards. Physicians were required to select one of a number of intended uses listed on the form. MAIN OUTCOME MEASURES: Data on albumin and serum protein levels; number o…

pharmacymedicine.medical_specialtySerum albuminPharmacistHospital DepartmentsPharmacyUnnecessary ProceduresSettore MED/42 - Igiene Generale E ApplicataHospitals UniversityInformed consentIntensive caremedicineHumansunder-use and over-useProspective Studiesappropriate healthcareMedical prescriptionProspective cohort studyIntensive care medicineprofessionSerum Albuminbiologybusiness.industryHealth PolicyPublic Health Environmental and Occupational HealthGeneral MedicineBlood ProteinsHuman serum albuminItalyEmergency medicinebiology.proteinappropriateneGuideline Adherencebusinessmedicine.drug
researchProduct

Adherence to treatment and quality of life of patients with hypertension during the COVID-19 pandemic

2023

Wprowadzenie: Ograniczenie dostępności do rutynowych wizyt kontrolnych w gabinetach lekarskich w czasie pandemii COVID-19, jak również niezgłaszanie się pacjentów z nadciśnieniem tętniczym do placówek ochrony zdrowia w obawie przed zakażeniem mogło zaburzyć współpracę lekarza z pacjentem i pogorszyć przestrzeganie zaleceń terapeutycznych. Cel pracy: Zbadanie jakości życia pacjentów z nadciśnieniem tętniczym oraz ocena przestrzegania przez nich zaleceń terapeutycznych podczas pandemii COVID-19. Materiał i metody: Zbadano 103 pacjentów SPZOZ MSWiA we Wrocławiu. Zastosowano Skróconą wersję ankiety oceniającej jakość życia (WHOQOL-BREF) oraz Skalę adherence w chorobach przewlekłych (ACDS). Wyni…

przestrzeganie zaleceń lekarskichhypertensionquality of lifepatient adherenceCOVID-19jakość życiapatientpacjentnadciśnienie tętniczeStudia Medyczne
researchProduct

Off-Adherence Keeping (OAK) observational study: intentional off-adherence immunomodulatory multiple sclerosis treatment

2022

Aims: To evaluate how improved treatment adherence with a lower-frequency regimen/treatment of intramuscular (IM) IFN beta-1a impacts therapeutic effectiveness in relapsing-remitting multiple sclerosis (MS) patients switching from a higher-frequency injectable regimen/treatment. Patients & methods: Italian patients with relapsing-remitting MS and prior poor adherence to high-frequency injectable treatments (n = 181) were followed for 24 months after starting IM IFN beta-1a. Results: During the study, 97.4% of patients were treatment adherent; 22.1% of patients reported a relapse. The estimated probability of remaining relapse-free after 2 years was 78%. A high dropout rate (52.5%) led t…

relapsesMultiple Sclerosis Relapsing-RemittingTreatment Outcomequality of lifeRecurrenceHumansSettore MED/26 - NeurologiaInterferon-betaNeurology (clinical)multiple sclerosistreatment adherenceInterferon beta-1aintramuscular interferon beta-1aNeurodegenerative Disease Management
researchProduct